EN | SE Contact us Careers

              Board of Directors

lekr.png

Leonard Kruimer

Chairman of the Board

Chairman of the Board since 2018. Member of the Remuneration Committee and the Audit Committee.

MBA, US.CPA. He served as a Board Member in BioInvent between 2016–2017. He was CFO and member of the board of Crucell NV from 1998 to 2011 and has held senior executive positions at Royal Boskalis N.V., GE Capital and Continental Can Company. Born 1958.

Other board appointments: Board member in Zealand Pharma A/S, Oncolytics Biotech Inc., Pharming Group and member of the Investment Advisory Council in Karmijn Kapitaal Investments.

Shareholding: 16,288
Independent in relation to the Company, senior executives, and major shareholders.

ves.png

Vessela Alexieva

Employee Representative

Member of the Board since 2013.

M.Sc. in Molecular and Functional biology. Senior Research Engineer. Born 1959.

Other board appointments: -

Shareholding: 932 (own and affiliated holdings)

Nabe

Natalie Berner

Member of the Board since 2022.

BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University. Previous Research Associate at the New York University School of Medicine. Currently Managing Director, Therapeutics at Redmile Group, LLC. Born 1990.

Other board appointments: Redx Pharma Plc

Shareholding: -
Independent in relation to the Company and senior executives. Dependent in relation to major shareholders.

krbi.png

Kristoffer Bissessar

Member of the Board since 2020.
Chairman of the Audit Committee.

Broad experience from the financial industry, operative in banking and finance between 1989 – 2012, with experience from asset management, institutional equity sales and investment banking. Previously held senior positions at Svenska Handelsbanken AB, Deutsche Bank AG and Nordea Bank AB and served as board member of the Swedish Securities Dealers Association. Board member of BioInvent during 2018-2019. Born 1968​.

Other board appointments: CEO and board member of Evolvere Partners AB.

Shareholding: 15,000
Independent in relation to the Company, senior executives, and major shareholders.

 

dch.png

Dharminder Chahal

Member of the Board since 2017. Member of the Audit Committee.

M.Sc. in Aerospace Engineering and M.Sc. in Business Economics. CEO and co-founder of SkylineDx, managing director of Sairopa B.V. and owner of Exponential B.V. in which capacity he acts as an consultant to Van Herk Investments. He has an extensive board experience in life science companies, with previous board assignments in for example Agendia, deVGen, Innate Pharma, Isobionics and Octoplus. Board member of BioInvent during 2013–2016 and 2017 onwards. Currently Fund Manager for Swanbridge Capital. Born 1976.

Other board appointments: Board member of Immunicum, Vitalnext, Ceradis, Medis Medical Imaging, Sensara and Anemones Hospitality and Hotels. He is advisory boardmember of BioGeneration Ventures ll, Thuja Capital Fund l and Gilde Healthcare Funds ll and lll.

Shareholding: 290,000
Independent in relation to the Company and senior executives. Dependent in relation to major shareholders.

The

Thomas Hecht

Member of the Board since 2020. Chairman of the Remuneration Committee and member of the Science Committee.

Doctor of Medicine. Previously experience as Vice President Marketing at Amgen Europe, and has held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, Thomas Hecht was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany. Currently Managing Partner at HHC Healthcare Consulting. Born 1951.

Other board appointments: Chairman of the board of Orion Biotechnology Ltd., Affimed N.V., and Aelix Therapeutics S.L. 

Shareholding: -
Independent in relation to the Company, senior executives, and major shareholders.

Nalu

Nanna Lüneborg

Member of the Board since 2022.

PhD in Neuroscience from University College London, MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford. Currently General Partner at Forbion. Prior experience with Apposite Capital and  Novo Ventures, one of the largest healthcare investors globally, where Nanna was a key member of the European deal team focusing on late-stage biopharma investments across Europe. Nanna Lüneborg has previously served on the Board of Directors of publicly traded and privately held companies, Lava Therapeutics (LVTX), Numab (private), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private). Born 1975.

Other board appointments: -

Shareholding: -
Independent in relation to the Company, senior executives, and major shareholders.

vin.png

Vincent Ossipow

Member of the Board since 2021. Member of the Science Committee.

CFA Charter, Ph.D. in Molecular Biology. Partner of Omega Funds and Chief Scientific Officer of Omega Alpha SPAC. He served as a Board Member in BioInvent between 2016–2020. Former partner in Private Equity Sectoral Asset Management. Researcher at University of Geneva. Research analyst at Pictet Bank. Born 1968.

Other board appointments: Board member of Sophia Genetics, Etherna Immuno-Oncology, Immunic, SwissThera and FoRx Therapeutics and board observer of Anaconda Brain.

Shareholding: -
Independent in relation to the Company, senior executives, and major shareholders.

Map

Martin Pålsson

Employee Representative

Member of the Board since 2022.
Martin has worked in the pharma and biotech industry since 2003 (QPharma, Novozymes and Repligen), and has extensive experience in GMP and chromatography. Born 1979.

Other board appointments: -

Shareholding: -

bese.png

Bernd Seizinger

Member of the Board since 2018. Chairman of the Science Committee, and member of the Remuneration Committee.

Doctor of Medicine and Doctor of Neurobiology. Previous experience as CEO and President of GPC Biotech, Executive Vice President and Chief Scientific Officer at Genome Therapeutics Corporation and Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances, both at Bristol-Myers Squibb. Senior faculty positions at Harvard Medical School, Massachusetts General Hospital, and Princeton University. Born 1956.

Other board appointments: Board member and chairman of multiple public and private biotech companies in the United States, Europe, and Canada, including Oxford BioTherapeutics, CryptoMedix Inc., Oncolytics Biotech Inc., Aprea AB and Vaccibody AS. Advisory board member/Senior Advisor to Biotech Venture Capital Funds such as BB Pureos Bioventures and Hadean Ventures.

Shareholding: 30,000
Independent in relation to the Company, senior executives, and major shareholders.